Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Clinical Oncology》 2009-05
Add to Favorite Get Latest Update

Clinical study of TACE combined sorafenib on advanced hepatocellular carcinoma

HAN Guo-hong,BAN Wei,LIANG Jie,YIN Zhan-xin,HE Chuang-ye,SONG Han-ge,WU Kai-chun,DING Jie,FAN Dai-ming.Department of Gastroenterology,the Affiliated Xijing Hospital to Fourth Military Medical University,Xi'an 710032,China  
Objective:To investigate the therapeutic effect and adverse reaction of transcatheter arterial chemoembolization(TACE) plus sorafenib on advanced hepatocelluar carcinoma.Methods:According to the test criteria,17 patients with HCC which was pathologically confirmedd or clinically diagnosed were enrolled and underwent TACE,and then they were administered with sorafenib(400mg for twice per day).the tumor response was evaluated according to RECIST criteria following every 4-6 weeks,and the reverse reaction were recorded.Results:No partial remission condition were observed in these patients,and among 12 patients who were evaluated,10 of them gain stable condition.The total survival rate of these patients was 76.5% during the observation.The total reverse reaction rate was 82.3%,most of them were released after treatment.Conclusion:TACE combined with sorafenib has achieved stable condition in patients with advanced HCC,which provided a new therapeutic modality,and futher studies are needed to confirm the efficacy and adverse events for intermediate and advanced HCC.
【CateGory Index】: R735.7
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved